Antiepileptic Drugs (AEDs) and Oral Contraceptives

Deep Dive

From a western clinical perspective, the relationship between antiepileptic drugs (AEDs) and oral contraceptives is defined by predictable pharm... From a western clinical perspective, the relationship between antiepileptic drugs (AEDs) and oral contraceptives is defined by predictable pharmacokinetic interactions. Several AEDs induce hepatic enzymes (CYP3A4 and/or UGT), accelerating the metabolism of ethinyl estradiol and progestins. Carbamazepine, phenytoin, phenobarbital, primidone, oxcarbazepine/eslicarbazepine, rufinamide, felbamate, cenobamate, perampanel at higher doses, and high‑dose topiramate are well‑documented examples. When these drugs are co‑administered with combined pills, patches, rings, the progestin‑only pill, or the etonogestrel implant, hormone exposure falls, increasing the likelihood of breakthrough bleeding and unintended pregnancy. Notably, the same enzyme induction decreases the effectiveness of oral emergency contraception; guideline bodies therefore prioritize a copper IUD as the most reliable emergency option when enzyme inducers are present. The reverse interaction is equally important: estrogens in combined hormonal contraceptives induce UGT1A4, lowering lamotrigine concentrations by roughly half during active pill weeks, with levels rebounding during hormone‑free intervals. These fluctuations can destabilize seizure control or provoke adverse effects. Most other non‑inducing AEDs (e.g., levetiracetam, gabapentin, pregabalin, lacosamide) have minimal effects on contraceptive steroids, while valproate is not an inducer but carries significant teratogenic risk, underscoring the need for reliable contraception until an optimal regimen is established. Management focuses on contraceptive methods unaffected by enzyme induction: copper and levonorgestrel IUDs, and DMPA injections, which maintain high effectiveness even with strong inducers. If oral or implantable hormonal methods are chosen in the presence of inducers, clinicians may advise backup barrier use and vigilance for bleeding changes. For individuals on lamotrigine starting or stopping estrogen-containing contraception, therapeutic drug monitoring and coordinated care between neurology and OB‑GYN help prevent seizure breakthrough or toxicity during the pill‑free interval. In pregnancy planning, shared decision-making addresses teratogenicity profiles (avoiding or minimizing valproate exposure when possible), preconception folic acid supplementation, and careful preconception adjustments with close monitoring. Clear communication about all prescription drugs, over‑the‑counter agents, and supplements is integral, because herbal products such as St. John’s wort can further reduce contraceptive effectiveness, and foods like grapefruit juice can increase levels of some AEDs (e.g., carbamazepine), risking toxicity. The overarching clinical aim is to enable informed contraceptive choices while preserving seizure stability and safeguarding pregnancy outcomes.